Tauklarify (florquinitau F 18 injection, also called MK-6240) is a brain PET tracer that binds aggregated tau and lights up tangles. The FDA approved it Aug. 14, 2026 for adults with cognitive impairment evaluated for Alzheimer's disease, but clinic availability and coverage remain uncertain, according to Lantheus in the FDA approval announcement.
Tau tangles are clumps of tau protein seen in Alzheimer's disease. The scan complements amyloid PET and other tools to help memory clinics stage disease. It does not treat Alzheimer's.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What does the scan do?
- How well did readers agree with pathology?
- How does it compare with Tauvid?
- What should patients ask before a scan?
What does the scan do?
Tauklarify is an F 18-labeled radioactive diagnostic. It binds aggregated tau protein during PET and makes tangles visible.
Clinicians use the image with other results to assess Alzheimer's-related pathology. It is the second FDA-cleared tau PET agent. The first was Eli Lilly's Tauvid (flortaucipir F 18), approved in 2020 to estimate density and distribution of aggregated tau tangles.
How well did readers agree with pathology?
FDA approval rested on two blinded-read studies with 617 participants from three trials. Five independent readers reached 68%-88% positive agreement and 93%-99% negative agreement, with strong interreader agreement, according to NeurologyLive in the blinded-read results. Agreement was summarized with Fleiss kappa values of 0.92 and 0.86. High negative agreement means a clearly negative read was usually consistent.
Positive reads varied more across readers. Labeling keeps use focused on Alzheimer's evaluation. Practical Neurology notes that safety and effectiveness are unestablished for non-Alzheimer's tauopathies. Performance may be lower at earlier pathologic stages, and a negative scan does not exclude tau pathology while a positive scan does not confirm it.
How does it compare with Tauvid?
The HEAD study compared MK-6240 directly with flortaucipir in the same participants. It was a prospective multicenter study with 682 completers, published in The Lancet in May 2026. MK-6240 discriminated Alzheimer's-related impairment better than flortaucipir, with AUC 0.93 versus 0.86.
It also detected tau more than twice as often in cognitively unimpaired people, according to AuntMinnie's summary of The Lancet in the HEAD study summary. That added sensitivity may matter for early staging and research. It does not by itself set a diagnosis or treatment choice.
What should patients ask before a scan?
Safety data in 1,734 subjects showed infrequent reactions. Labeling still warns about misdiagnosis risk and cumulative radiation exposure. It advises hydration and voiding, avoiding CYP1A2 inducers including smoking for 7 days, and interrupting lactation for 4 hours after the dose.
Near-term access is uncertain. Lantheus said it will support therapeutic programs through Pharma Solutions while assessing broader commercial availability. Medicare has left dementia PET coverage to regional contractors since Jan. 1, 2022, rather than setting one national rule.
- Ask whether the memory clinic offers Tauklarify or Tauvid
- Ask what the regional Medicare contractor covers and what prior authorization is needed
- Ask how to prepare, including medicines, smoking, hydration, and lactation plans
- Ask how the tau result will change staging, referrals, or treatment decisions
You Might Also Like
- The Third FDA-Cleared Alzheimer’s Blood Biomarker Test in 2026: What Is Established and What Remains Uncertain for Memory Clinic Patients
- PrecivityAD2 and Younger-Onset Alzheimer’s Diagnosis in 2026: What Is Established and What Remains Uncertain for Memory Clinic Patients
- PrecivityAD2 as an Adjunct to a 2026 Alzheimer’s Assessment: What Is Established and What Remains Uncertain for Memory Clinic Patients





